Caldera says third study of PSA-test alternative shows high ability to spot Prostate cancer

Jonathan Underhill
Thu, 15 Sep 2016

By Jonathan Underhill Sept. 15 (BusinessDesk) - Caldera Health, a New Zealand biotech company working on a gene-sequencing replacement for the world’s most widely used prostate cancer test, says its third clinical test has shown a strong ability to identify prostate cancer and screen out those who test negative. The company is working on a replacement for the widely used PSA blood test with a simple “pee in a pot” test, using RNA biomarkers. In 2012, the US Preventive Services Task Force recommended against mass PSA screening because it t...

Not convinced yet?

Subscribe to our Daily News Update free newsletter.

The Quiz FREE
QuiznessDesk, Tuesday, July 05, 2022
The Quizmaster | Tue, 05 Jul 2022

Don't forget to give our daily quiz a go. Good luck

Law & Regulation
Juice magnate Lepionka sues lawyers for 'negligent' advice
Greg Hurrell | Tue, 05 Jul 2022

Businessman Stefan Lepionka's negligence case against Gibson Sheat will be split in two, with the law firm's countersuit to be heard first, the high court has ruled.

George Kerr's Pyne Gould receivership continues
Victoria Young | Tue, 05 Jul 2022

Court action continues in the UK, while receivers have already clawed back $8m for the BNZ by selling South Island land.

How can Kiwi small business owners manage rising inflation?

Xero MD Craig Hudson says small businesses have been hit with a triple whammy.

Digital innovation could shape the future of NZ

The digital age allows us to collaborate on some of our greatest scientific and environmental challenges